Abstract: The present invention relates to relates to T cell epitope peptides, proteins, nucleic acids and cells for use in immunother-apeutic methods. In particular, the present invention relates to the immunotherapy of viral infection. The present invention specifically relates to virus-associated T-cell peptide epitopes, alone or in combination with other virus-associated peptides that can serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-viral immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Abstract: A night light includes a housing, a dimmable light source operatively connected to a rotatable light source controller rotatable about an axis and at least one first sensor mounted within the housing operative to sense rotation of the rotatable light source. The at least one first sensor outputs a signal representative of the rotation. Further, the rotatable light source can be rotated by a hand of a user. Still further, the light night can be controlled via wireless communication.

Abstract: An electric door release system and an electric door release method are disclosed. The system and method may be used for releasing a vehicle door when a primary power source of the vehicle is drained. According to certain embodiments, the system includes a power interface configured to receive a direct-current (DC) power from an external mobile device. The system also includes one or more door latches. The system further includes an isolation circuitry configured to prevent the DC power from powering circuitry not included in the electric door release system. The system further includes a controller configured to activate a door latch using the DC power.

Abstract: A universal serial bus (USB)-powered utility tool includes a housing defining an interior space, at least one dimmable light source positioned on one side of the housing and a USB connector extending outwardly from the housing. The USB connector may be positioned on another side of the housing. The USB connector may be positioned orthogonal to the at least one dimmable light source. The USB-powered utility tool may further include a printed circuit board (PCB) positioned orthogonal to the USB connector. The USB-powered utility tool may further include a processor logic configured to control a current being supplied to the at least one dimmable light source. The at least one dimmable light source may be controlled manually or via wireless communication.

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer, in particular myeloma. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Abstract: A night light includes a housing, a dimmable light source operatively connected to a rotatable light source controller rotatable about an axis and at least one first sensor mounted within the housing operative to sense rotation of the rotatable light source. The at least one first sensor outputs a signal representative of the rotation. Further, the rotatable light source can be rotated by a hand of a user. Still further, the light night can be controlled via wireless communication.

Abstract: A universal serial bus (USB)-powered utility tool includes a housing defining an interior space, at least one dimmable light source positioned on one side of the housing and a USB connector extending outwardly from the housing. The USB connector may be positioned on another side of the housing. The USB connector may be positioned orthogonal to the at least one dimmable light source. The USB-powered utility tool may further include a printed circuit board (PCB) positioned orthogonal to the USB connector. The USB-powered utility tool may further include a processor logic configured to control a current being supplied to the at least one dimmable light source. The at least one dimmable light source may be controlled manually or via wireless communication.

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to several novel peptide sequences and their variants derived from HLA class I and HLA class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.

Abstract: A night light includes a housing, a dimmable light source operatively connected to a rotatable light source controller rotatable about an axis and at least one first sensor mounted within the housing operative to sense rotation of the rotatable light source. The at least one first sensor outputs a signal representative of the rotation. Further, the rotatable light source can be rotated by a hand of a user. Still further, the light night can be controlled via wireless communication.

Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to several novel peptide sequences and their variants derived from HLA class I and HLA class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.